Yesterday, Olaplex released its financial report of Q3 in 2025. It reported a modest sales decline for the third quarter, though results came in ahead of Wall Street expectations.
Net sales fell 3.8 percent year over year to $114.6 million, exceeding analysts’ forecasts of $111 million. Net income totaled $11.1 million, compared with $14.8 million in the same period last year, while diluted earnings per share stood at 2 cents.
By channel, specialty retail sales dropped 13.5 percent to $36.9 million, professional sales rose 5.3 percent to $44.5 million, and direct-to-consumer sales decreased 2.9 percent to $33.3 million. U.S. sales declined 14.6 percent, while international revenue increased 7.1 percent.
Chief executive officer Amanda Baldwin, who took the helm in 2023, said the company continues to make steady progress toward its transformation goals. “We’ve got to keep going at that and really executing against our vision,” she said. “We’re starting to see the fruits of that labor.”
Baldwin highlighted the strength of the professional business, noting that Olaplex is investing in a “pro-first and pro-early strategy” that is beginning to show results. She also acknowledged ongoing efforts to improve retail performance, emphasizing that the turnaround will take time. “It’s not going to happen overnight. It’s not linear, but we’re making some nice progress,” she said, adding that consumer response to the brand’s rebranding efforts has been positive.
The earnings report follows Olaplex’s recent acquisition of Purvala Bioscience, a Boston-based biotechnology company. The deal marks Olaplex’s first acquisition since its founding more than a decade ago. Baldwin said the move positions the brand for its “next frontier in science,” providing access to new technologies that will support future product innovation.
